Get started
Author

Gabriel De Avila

Observed names: Gabe de Avila, Gabriel de Avila
OpenAlex ID: A5035860017
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
2025 · Doris K. Hansen, Lauren C. Peres, et al. · Journal of Clinical Oncology · 54
Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes
2024 · Ciara L. Freeman, Jerald Noble, et al. · Blood · 43
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience
2023 · Hamza Hashmi, Doris K. Hansen, et al. · Haematologica · 33
PDF
Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy
2023 · Lauren C. Peres, Laura B. Oswald, et al. · Blood Advances · 29
PDF
Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma
2021 · AGM Mostofa, Allison Distler, et al. · JCI Insight · 25
PDF
Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy
2023 · Othman S. Akhtar, Karnav Modi, et al. · Transplantation and Cellular Therapy · 24
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
2025 · Danai Dima, Mariola A. Vazquez-Martinez, et al. · Blood Cancer Journal · 18
PDF
High Metabolic Tumor Volume Is Associated with Higher Toxicity and Decreased Efficacy of BCMA CAR-T Cell Therapy in Multiple Myeloma
2022 · Ricardo Villanueva, Doris K. Hansen, et al. · Blood · 16
IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF-κB– and caspase-8–dependent mechanisms
2021 · Liang Zhou, Yu Zhang, et al. · Blood Advances · 16
Metabolic Changes Are Associated with Melphalan Resistance in Multiple Myeloma
2021 · David C. Koomen, Mark B. Meads, et al. · Journal of Proteome Research · 12
Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy
2022 · Lauren C. Peres, Laura B. Oswald, et al. · Blood · 10
Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
2024 · Danai Dima, Mariola A Vazquez-Martinez, et al. · Blood · 9
Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel
2023 · Laura B. Oswald, Lisa M. Gudenkauf, et al. · Cancers · 8
PDF
Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality
2025 · Surbhi Sidana, Brett Reid, et al. · Blood · 7
Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience
2022 · Hamza Hashmi, Doris K. Hansen, et al. · Blood · 7
Bridging therapy response and low pre-lymphodepletion plasma cell burden are associated with improved safety and efficacy outcomes of ciltacabtagene autoleucel in multiple myeloma
2025 · Doris Hansen, Brett Reid, et al. · Blood · 5
PDF
Post-progression outcomes following BCMA-directed CAR T-cell therapy in myeloma: impact of extramedullary and paramedullary disease
2025 · Ziad Abuhelwa, Fnu Amisha, et al. · Frontiers in Oncology · 5
PDF
Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myeloma
2025 · Stefanie Palfi, Lauren C. Peres, et al. · Blood Cancer Journal · 5
PDF
Sarcopenia Prevalence and Influence on the Development of Toxicity and Length of Stay in Patients with Relapsed and Refractory Myeloma Treated with Commercial Anti-BCMA CART Cells
2022 · Nathan Parker, Karnav Modi, et al. · Blood · 5
Reinforcement Learning to Optimize the Treatment of Multiple Myeloma
2019 · Kenneth H. Shain, Daniel Hart, et al. · Blood · 5
Cytopenias and infections following ciltacabtagene autoleucel in heavily-pretreated relapsed or refractory multiple myeloma
2025 · Danai Dima, Jennifer M. Logue, et al. · Haematologica · 4
PDF
A Pro-Inflammatory State and Peak Cytokines Are Associated with Toxicity and Early Responses in Real-World Multiple Myeloma Patients Treated with Idecabtagene Vicleucel
2023 · Doris K. Hansen, Lauren C. Peres, et al. · Blood · 4
Single Center Real World Experience of Talquetamab in Patients with Relapsed and Refractory Multiple Myeloma
2024 · Ariel F. Grajales-Cruz, Allison Graeter, et al. · Blood · 3
PDF
Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma
2024 · Doris K. Hansen, Lauren C. Peres, et al. · Blood · 3
PDF
Baseline Systemic Inflammatory Markers Interleukin 6 and Ferritin Are Associated with Toxicities and Progression-Free Survival in Multiple Myeloma Patients Treated with Idecabtagene Vicleucel
2022 · Doris K. Hansen, Lauren C. Peres, et al. · Blood · 3
Works count: 74
Citation count: 391
H-index: 10
I10-index: 11
Year
Topic
Type